Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

IICA Technology Expo explored instrumentation, control & automation

PakTech moves into the Australian market

Low-carbon aviation? Try methane

Healthcare waste recycling initiative to repurpose IV bags

Govt sustainability initiatives welcomed by Engineers Australia

eHealth NSW Chief Dr Zoran Bolevich to lead AIHW

SJG Bendigo Hospital expands cardiac care service

Midwifery Group Practice model highly valued in rural areas: report

Better use of data could save $5.4bn in hospital costs: PC

Immersive reality for improved healthcare delivery

ARM Hub forms partnership with Databricks

ABB launches latest version of flagship DCS

New research dedicated to sustainable and resilient supply chains

Siemens unveils software-based automation technology

Rockwell Automation adds GenAI to Fiix Asset Predictor

Lonza bone marrow and cord blood mononuclear cells

AlphaThera oYo-Link Antibody Labeling Reagents

Bio-Rad Laboratories StarBright Red 715, 775 and 815 Dyes and expanded antibody markers

RevMAb Biosciences histone family protein monoclonal antibodies

Content from other channels on our network